

mononuclear cells and gut-associated lymphatic tissues obtained from HIV-1 patients undergoing cART also found no evidence of *de novo* viral replication (13).

In contrast, other studies have reported continuous virus replication during combined chemotherapy (10, 12). One possible explanation for this discrepancy is the thorough suppression of the plasma viral burden, <20 copies/ml at necropsy, that was achieved in this study (18). *De novo* virus replication was detected in HIV-1-infected patients whose plasma viral RNA burdens ranged from 20 to 400 copies/ml but not in those with <20 copies/ml (24). Our findings also indicate that the cART regimen we used (18) was robust enough to halt viral evolution nearly completely in animals.

Our sample size, an average of 10 sequences from each specimen, may conceivably have limited our ability to detect minor populations with signs of ongoing replication. An analysis of four animals, however, did not reveal the genotypes detailed in the present study. Therefore, while our results cannot rule out possible *de novo* viral replication during cART, the data indicate that it is not a major mode of viral persistence in individuals whose virus replication levels are thoroughly suppressed by cART.

The locations of other potential viral reservoirs, in addition to resting CD4<sup>+</sup> T lymphocytes, an already established HIV/SIV reservoir found to be present in blood (25–28), lymph nodes (25), and the spleen (29), remains elusive. While the cART regimen we developed suppressed viral RNA levels nearly completely in the circulation and fairly well in effector sites, such as the gastrointestinal tract and lungs, viral RNA expression levels in lymph nodes were not contained effectively (18), suggesting that the viral reservoir consists of cells present in lymph nodes. We also detected CD3-positive cells, most likely CD4<sup>+</sup> T lymphocytes, expressing Nef protein in the follicles of the MLN of an SIV-infected animal that exhibited a viral rebound upon the cessation of cART (18). On the basis of their location, these might be Tfh cells, which are of the memory phenotype (30–32). The results of the present study have further narrowed the location of the viral reservoir from our previous study (18) to cells with longer half-lives that retain provirus for at least 1 year. Since resting CD4<sup>+</sup> T cells possess long half-lives (33), these cells satisfy this criterion for a viral reservoir during cART. It is conceivable that resting CD4<sup>+</sup> T cells functioned as the predominant viral reservoir in the SIV239-rhesus macaque model for patients undergoing cART employed in our study, as in preceding studies concerning the issue in the context of HIV and SIV infections.

Lymph nodes serve as a major HIV reservoir throughout the course of infection without intervention by cART (15–17). During clinical latency, the virus persists as an intact provirus, which can produce infectious viral particles upon cell activation, in a minuscule fraction of the resting CD4<sup>+</sup> T lymphocytes in lymph nodes (25). An extensive examination of lymph node specimens from HIV patients undergoing cART revealed an infinitesimal amount of viral RNA-positive cells by *in situ* hybridization (34). Hockett et al. (34) revealed that cART lowers the number of viral RNA-positive cells in lymph nodes but that the number of viral copies in each infected cell is constant, regardless of the viral burden in the circulation, suggesting the existence of virus-infected cells actively transcribing viral genes during cART, as we found previously in the lymph nodes of SIV239-infected animals undergoing cART (18). Our present observations, together with those of Hockett et al. (34), indicate that the viral RNA-positive cells present in lymph

nodes during cART may represent cells infected with virus prior to the initiation of cART and transcribing viral RNA from integrated provirus during therapy.

Current cART is unable to eradicate the viral reservoir or, more precisely, provirus integrated in the reservoir. On the basis of our results, it is important to establish strategies to target specifically long-lived cells that harbor intact provirus while unlocking the dormant state of the provirus, perhaps by using histone deacetylase (35), to achieve a functional cure for AIDS.

## ACKNOWLEDGMENTS

We are grateful to Tetsuro Matano for encouraging the initiation of this study, Beatrice H. Hahn for providing the protocol for SGA, and former and current members of the Igarashi laboratory for discussion and support.

This work was supported by Research on HIV/AIDS grants (H20-AIDS Research-003, H22-AIDS Research-007, and H24-AIDS Research-008) from The Ministry of Health, Labor and Welfare of Japan and by a Grant-in-Aid for Scientific Research (B) (23300156) from the Japan Society for the Promotion of Science.

## REFERENCES

- Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. *N. Engl. J. Med.* 337:734–739.
- Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Jr, Feinberg JE, Balfour HH, Jr, Deyton LR, Chodakewitz JA, Fischl MA. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. *N. Engl. J. Med.* 337:725–733.
- Perelson AS, Essunger P, Cao Y, Vesanen M, Hurlley A, Saksela K, Markowitz M, Ho DD. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. *Nature* 387:188–191.
- Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH. 2000. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *N. Engl. J. Med.* 342:921–929.
- Autrán B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J. 1997. Positive effects of combined antiretroviral therapy on CD4<sup>+</sup> T cell homeostasis and function in advanced HIV disease. *Science* 277:112–116.
- Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F, Schellekens PT. 1998. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. *Nat. Med.* 4:208–214.
- Zhang ZQ, Notermans DW, Sedgewick G, Cavert W, Wietgreffe S, Zupancic M, Gebhard K, Henry K, Boies L, Chen Z, Jenkins M, Mills R, McDade H, Goodwin C, Schuurth CM, Danner SA, Haase AT. 1998. Kinetics of CD4<sup>+</sup> T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. *Proc. Natl. Acad. Sci. U. S. A.* 95:1154–1159.
- Antiretroviral Therapy Cohort Collaboration. 2008. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet* 372:293–299.
- Chun TW, Davey RT, Jr, Engel D, Lane HC, Fauci AS. 1999. Re-emergence of HIV after stopping therapy. *Nature* 401:874–875.
- Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. *Science* 278:1291–1295.
- Shen L, Siliciano RF. 2008. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. *J. Allergy Clin. Immunol.* 122:22–28.
- Anderson JA, Archin NM, Ince W, Parker D, Wiegand A, Coffin JM, Kuruc J, Eron J, Swanstrom R, Margolis DM. 2011. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4<sup>+</sup> T cells. *J. Virol.* 85:5220–5223.

13. Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, Mohri H, Markowitz M. 2012. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. *PLoS Pathog.* 8:e1002506. doi: 10.1371/journal.ppat.1002506.
14. Martínez MA, Cabana M, Ibanez A, Clotet B, Arno A, Ruiz L. 1999. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. *Virology* 256:180–187.
15. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. *Nature* 362: 359–362.
16. Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, Kotler DP, Fauci AS. 1991. Lymphoid organs function as major reservoirs for human immunodeficiency virus. *Proc. Natl. Acad. Sci. U. S. A.* 88:9838–9842.
17. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. *Nature* 362:355–358.
18. Horiike M, Iwami S, Kodama M, Sato A, Watanabe Y, Yasui M, Ishida Y, Kobayashi T, Miura T, Igarashi T. 2012. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. *Virology* 423:107–118.
19. Leitner T, Albert J. 1999. The molecular clock of HIV-1 unveiled through analysis of a known transmission history. *Proc. Natl. Acad. Sci. U. S. A.* 96:10752–10757.
20. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI. 1999. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. *J. Virol.* 73:10489–10502.
21. Burns DP, Desrosiers RC. 1991. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. *J. Virol.* 65:1843–1854.
22. Johnson PR, Hamm TE, Goldstein S, Kitov S, Hirsch VM. 1991. The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques. *Virology* 185:217–228.
23. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, Manigart O, Mulenga J, Anderson JA, Swanstrom R, Haynes BF, Athreya GS, Korber BT, Sharp PM, Shaw GM, Hahn BH. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. *J. Virol.* 82:3952–3970.
24. Günthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD. 1998. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. *J. Virol.* 72:2422–2428.
25. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. *Nature* 387:183–188.
26. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. 1995. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. *Nat. Med.* 1:1284–1290.
27. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc. Natl. Acad. Sci. U. S. A.* 94:13193–13197.
28. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science* 278:1295–1300.
29. Shen A, Zink MC, Mankowski JL, Chadwick K, Margolick JB, Carruth LM, Li M, Clements JE, Siliciano RF. 2003. Resting CD4<sup>+</sup> T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-*Macaca nemestrina* model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. *J. Virol.* 77:4938–4949.
30. Lindqvist M, van Lunzen J, Soghoian DZ, Kuhl BD, Ranasinghe S, Kranias G, Flanders MD, Cutler S, Yudanin N, Muller MI, Davis I, Farber D, Hartjen P, Haag F, Alter G, Schulze zur Wiesch J, Streeck H. 2012. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. *J. Clin. Invest.* 122:3271–3280.
31. Lütthje K, Kallies A, Shimohakamada YT, Belz GT, Light A, Tarlinton DM, Nutt SL. 2012. The development and fate of follicular helper T cells defined by an IL-21 reporter mouse. *Nat. Immunol.* 13:491–498.
32. Weber JP, Fuhrmann F, Hutloff A. 2012. T-follicular helper cells survive as long-term memory cells. *Eur. J. Immunol.* 42:1981–1988.
33. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4<sup>+</sup> T cells. *Nat. Med.* 9:727–728.
34. Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, Chiz S, Nowak MA, Shaw GM, Bucy RP. 1999. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. *J. Exp. Med.* 189:1545–1554.
35. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. *Nature* 487:482–485.
36. Tamura K, Nei M. 1993. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. *Mol. Biol. Evol.* 10:512–526.
37. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol. Biol. Evol.* 28:2731–2739.
38. Felsenstein J. 1981. Evolutionary trees from DNA sequences: a maximum likelihood approach. *J. Mol. Evol.* 17:368–376.

# In vitro and In vivo Resistance to Human Immunodeficiency Virus Type 1 Entry Inhibitors

Yosuke Maeda<sup>1</sup>, Kazuhisa Yoshimura<sup>2</sup>, Fusako Miyamoto<sup>3</sup>, Eiichi Kodama<sup>3</sup>, Shigeyoshi Harada<sup>2</sup>, Yuzhe Yuan<sup>5</sup>, Shinji Harada<sup>1</sup> and Keisuke Yusa<sup>5\*</sup>

<sup>1</sup>Department of Medical Virology, Graduate School of Medical Virology, Kumamoto University, Honjo 2-1-1, Kumamoto 860-5886, Japan  
<sup>2</sup>Center for AIDS Research, Kumamoto University, Kumamoto 860-0811, Japan  
<sup>3</sup>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan  
<sup>4</sup>Transfusion transmitted Diseases Center, Institute of Blood Transfusion, Chinese Academy of Medical Science, #26 Hua-Cai Road, Long-Tan-Si Industrial Park, Chenghua District, Chengdu, 610052 Sichuan Province, P. R. China  
<sup>5</sup>Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kami-youga 1-18-1, Setagaya, Tokyo 158-8501, Japan

**Abstract**  
Viral entry is one of the most important targets for the efficient treatment of Human immunodeficiency virus type 1 (HIV-1)-infected patients. The entry process consists of multiple molecular steps: attachment of viral gp120 to CD4, interaction of gp120 with CCR5 or CXCR4 co-receptors, and gp41-mediated fusion of the viral and cellular membranes. Understanding the sequential steps of the entry process has enabled the production of various antiviral drugs to block each of these steps. Currently, the CCR5 inhibitor, maraviroc, and the fusion inhibitor, enfuvirtide, are clinically available. However, the emergence of HIV-1 strains resistant to entry inhibitors, as commonly observed for other classes of antiviral agents, is a serious problem. In this review, we describe a variety of entry inhibitors targeting different steps of viral entry and escape variants that are generated *in vitro* and *in vivo*.


**Keywords:** CD4-gp120 binding inhibitor; CCR5 antagonist; CXCR4 antagonist; Fusion inhibitor; Resistance; HIV-1

## Introduction

The development of chemotherapy with antiretroviral agents has reduced the morbidity and mortality of Human immunodeficiency virus type 1 (HIV-1)-infected individuals. Successful treatment of HIV-1-infected patients using chemotherapy is partly due to a combination of different classes of antiviral agents against the viral protease or reverse transcriptase. However, successful eradication of the virus from infected individuals has not been achieved by antiviral treatment, and is often limited by the emergence of drug-resistant HIV-1 strains [1-3]. These problems highlight the need to develop novel anti-HIV-1 drugs that target different steps of the viral replication process. Viral entry is currently one of the most attractive targets for the development of new drugs to control HIV-1 infection. Viral entry proceeds through Env

(gp120, gp41)-mediated membrane fusion, and consists of sequential steps: (i) attachment of viral gp120 to the CD4 receptor; (ii) binding of gp120 to CCR5 or CXCR4 co-receptors; and (iii) fusion of the viral and cellular membranes (Figure 1). A large number of inhibitors targeting different steps of the viral entry process have been developed, including peptides/peptide mimics, small molecules, and monoclonal antibodies (MAb).

Enfuvirtide (also known as T-20) was the first of a new class of drugs known as fusion inhibitors, which was approved by the U.S. Food and Drug Administration (FDA) in 2003. Approval was given for the use of this drug in combination with other anti-HIV-1 medications to treat advanced HIV-1 infection in adults and children aged six years and older. The drug is an antiviral peptide that prevents HIV-1 entry by blocking gp41-mediated fusion [4-6]. Small compounds that can bind to the pockets of the extracellular loops of a coreceptor are expected to be potent antiviral agents. Several small-molecule CCR5 inhibitors have progressed through clinical development [7]. Maraviroc [8,9], a CCR5 antagonist, is the second entry inhibitor approved by the FDA in 2007 for treatment-experienced patients infected with a CCR5-tropic (R5-tropic) virus. Extensive research is currently underway to develop the next generation of entry inhibitors, however, the emergence of viral strains resistant to entry inhibitors, as well as other classes of antiviral



**Figure 1:** Molecular targets of inhibitors of HIV-1 entry into the target cell.

**\*Corresponding author:** Keisuke Yusa, Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kami-youga 1-18-1, Setagaya, Tokyo 158-8501, Japan, Tel: +81-3-3700-1141 ext. 335; Fax: +81-3-3700-9084, E-mail: yusak@nihs.go.jp

**Received** October 18, 2011; **Accepted** December 02, 2011; **Published** December 05, 2011

**Citation:** Maeda R, Yoshimura K, Miyamoto F, Kodama E, Harada S, et al. (2011) *In vitro* and *In vivo* Resistance to Human Immunodeficiency Virus Type 1 Entry Inhibitors. J AIDS Clinic Res S2:004. doi:10.4172/2155-6113.S2-004.

**Copyright:** © 2011 Maeda R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

agents, has been reported *in vitro* and *in vivo* [7,10]. In this review, we describe the current status of *in vitro* and *in vivo* resistance to HIV-1 entry inhibitors.

### Resistance to CD4-gp120 binding inhibitors

**Inhibition of CD4-gp120 binding:** Entry of HIV-1 into target cells is mediated by the trimeric envelope glycoprotein complex, each monomer consisting of a gp120 exterior envelope glycoprotein and a gp41 transmembrane envelope glycoprotein [11]. Attachment of HIV-1 to the cell is initiated by the binding of gp120 to its primary CD4 receptor, which is expressed on the surface of the target cell. The gp120-CD4 interaction induces conformational changes in gp120 that facilitate binding to additional coreceptors (for example, CCR5 or CXCR4). Attachment inhibitors are a novel class of compounds that bind to gp120 and interfere with its interaction with CD4 [12]. Thus, these agents can prevent HIV-1 from attaching to the CD4+ T cell and block infection at the initial stage of the viral replication cycle (Figure 1). There are two primary types of HIV-1 attachment inhibitors: nonspecific attachment inhibitors and CD4-gp120 binding inhibitor [13].

In this section, we focus on the CD4-gp120 binding inhibitors, the soluble form of CD4 (sCD4), a fusion protein of CD4 with Ig (PRO542), a monoclonal anti-CD4 antibody (Ibalizumab, formerly TNX-355), CD4 binding site (CD4bs) monoclonal antibodies (b12 and VRC01), small-molecule HIV-1 attachment inhibitors (BMS-378806 and BMS-488043), and a new class of small-molecule CD4 mimics (NBD-556 and NBD-557) and a natural small bioactive molecule (Palmitic acid) (Figure 2). We also describe the resistance profiles against these CD4-gp120 binding inhibitors *in vivo* and/or *in vitro*.

**Soluble CD4 (sCD4) and PRO542:** In the late 1980s, various recombinant, soluble proteins derived from the N-terminal domains of CD4 were shown to be potent inhibitors of laboratory strains of HIV-1 [14]. Based on the potential of sCD4 to inhibit HIV-1 infection *in vitro*, this protein was tested for clinical efficacy in HIV-1-infected individuals; however, no effect on plasma viral load was observed [14]. Further examination revealed that doses of sCD4 significantly higher than those achieved in the clinical trial were required to neutralize primary clinical isolates of HIV-1, in contrast to the relatively sensitive, laboratory-adapted strains [15].

The first report of sCD4-resistant variants induced by *in vitro* selection showed that the resistant variant had a single mutation (M434T) in the C4 region [16]. During selection with sCD4, it was also reported that, seven mutations (E211G, P212L, V255E, N280K, S375N, G380R, and G431E) appeared during *in vitro* passage [17]. Further, a recombinant clone containing a V255E mutation was found to be highly resistant to sCD4 compared with the wild-type virus (114-fold higher 50% inhibitory concentration [IC<sub>50</sub>] value). To determine the mutation profiles obtained during *in vitro* selection with sCD4, the atomic coordinates of the crystal structure of gp120 bound to sCD4 was retrieved from public protein structure database (PDB entry: 1RZJ). From these analyses, it was determined that almost all the described resistance mutations were located the inside the CD4-binding cavity of gp120 [17].

Recently, a novel recombinant antibody-like fusion protein (CD4-IgG2; PRO542) was developed in which the Fv portions of both the heavy and light chains of human IgG2 were replaced with the D1D2 domains of human CD4 [18]. PRO542 was shown to broadly and po-

Profile of CD4-gp120 binding inhibitors

	Structure	Feature	Target	Resistant related mutations (region of gp160) [ref]
sCD4	Soluble form of CD4 domain1-4	First CD4-gp120 binding inhibitor	CD4 binding site of gp120	M434T (C4) [16], V255E(C2) [17]
PRO542	Tetavalent CD4 (domain1-2)-IgG	Developing for microbicide	CD4 binding site of gp120*	N/A
Ibalizumab	Anti-CD4 monoclonal antibody (Mab)	First-in-class, MAb inhibitor of CD4-mediated HIV entry	Domain 2 of CD4	N/A
b12	Anti-CD4 binding site Mab	Neutralizing around 40% of HIV-1 primary isolates	CD4 binding site of gp120	P369L (C3) [27]
VRC01	Anti-CD4 binding site Mab	Neutralizing over 90% of diverse HIV-1 primary isolates	CD4 binding site of gp120	K121A(C1), L179A(V2), T202A(C2), D279A(C2), R304A(V3), I420A(C4), I423A(C4), Y435A(C4), G471A(C5), D474A(C5) [31]
BMS-378806	see below Figure	First small molecule HIV-1 CD4 attachment inhibitor	CD4 binding site of gp120	V68A(C1), M426L(C4), M475I(V5), I595F(gp41) [33]
BMS-488043	see below Figure	improved <i>in vitro</i> antiviral activity and PK properties compared to BMS-378806	CD4 binding site of gp120	V68A(C1), L116I(C1), S375I/N(C3), M426L(C4) [34]
NBD-556	see below Figure	Inhibition of HIV-1 entry and enhancing neutralizing potency of Abs	CD4 binding site of gp120	S377N(C3), A433T(C4) [17], S375W(C3), I424A(C4), W427A(C4), V475A(C5) [38]
NBD-557	see below Figure	Inhibition of HIV-1 entry and enhancing neutralizing potency of Abs	CD4 binding site of gp120	N/A
Palmitic acid	CH <sub>3</sub> (CH <sub>2</sub> ) <sub>14</sub> COOH	A natural small bioactive molecule from <i>Sargassum fusiforme</i>	Domain 1 of CD4	N/A

\* N/A ; not available




Figure 2: Profile of CD4-gp120 binding inhibitors including molecular structures of selected small molecular inhibitors.

tently neutralize HIV-1 subtype B isolates, and was also able to neutralize strains from non-B isolates with the same breadth and potency as for subtype B strains. PRO542 blocks attachment and entry of the virus into CD4<sup>+</sup> target cells and were mainly developed for the prevention and transmission of HIV-1 through external application agents, such as microbicides.

**Ibalizumab (TNX-355):** Monoclonal anti-CD4 antibodies block the interaction between gp120 and CD4 and, therefore, inhibit viral entry [19]. Ibalizumab (formerly TNX-355) was a first-in-class, monoclonal antibody inhibitor of CD4-mediated HIV-1 entry [20]. By blocking CD4-dependent HIV-1 entry, ibalizumab was shown to be active against a broad spectrum of HIV-1 isolates, including recombinant subtypes, as well as both CCR5-tropic and CXCR4-tropic HIV-1 isolates. Many clinical trials with HIV-1-infected patients have demonstrated the antiviral activity, safety, and tolerability of ibalizumab. A nine-week phase Ib study investigating the addition of ibalizumab monotherapy to failing drug regimens showed transient reductions in HIV-1 viral loads and the evolution of HIV-1 variants with reduced susceptibility to ibalizumab. Further, clones with reduced susceptibility to ibalizumab contained fewer potential N-linked glycosylation sites (PNGSs) within the V5 region of gp120. Reduction in ibalizumab susceptibility due to the loss of V5 PNGSs was confirmed by site-directed mutagenesis [21].

**Monoclonal antibodies, b12 and VRC01:** Several broadly neutralizing MAbs isolated from HIV-1-infected individuals define conserved epitopes on the HIV-1 Env. These include the membrane proximal external region of gp41 targeted by MAbs 4E10 and 2F5 [22]; the carbohydrate-specific outer domain epitope targeted by 2G12 [23]; a V2-V3-associated epitope targeted by PG9/PG16 [24]; and the CD4bs [25] targeted by b12 and VRC01. The CD4bs overlaps with the conserved region on gp120 that is involved in the engagement of CD4. The prototypic CD4bs-directed MAb, b12, neutralizes around 40% of primary isolates, and its structure (in complex with the core of gp120) has been defined [26]. However, Mo et al. [27] reported the first resistant variant induced by *in vitro* selection with b12 that showed a P369L mutation in the C3 region of HIV-1<sub>JRCSF</sub>. Further, several b12-resistant viruses commonly display an intact b12 epitope on the gp120 subunits [28], suggesting that quaternary packing of Env also confers resistance to b12.

A recently described CD4bs-directed MAb, VRC01, had been shown to be able to neutralize over 90% of diverse HIV-1 primary isolates [29]. The structure of VRC01 in complex with the gp120 core reveals that the VRC01 heavy chain binds to the gp120 CD4bs in a manner similar to that of CD4 [30]. The gp120 loop D and V5 regions contain substitutions uniquely affecting VRC01 binding, but not b12 or CD4-Ig binding. In contrast to the interaction of CD4 or b12 with the HIV-1 Env, occlusion of the VRC01 epitope by quaternary constraints was not a major factor limiting neutralization. Interestingly, many Ala substitutions at non-contact residues increased the potency of CD4- or b12-mediated neutralization; however, few of these substitutions enhanced VRC01-mediated neutralization [31]. This study suggests that VRC01 approaches its cognate epitope on the functional spike with less steric hindrance than b12 and, surprisingly, with less hindrance than the soluble form of CD4 itself. These differences might be related to the distinctly different angle of approach to the CD4bs employed by VRC01, in contrast to the more loop-proximal approach employed by CD4 and b12.

**BMS-378806 and BMS-488043:** BMS-378806 (Figure 2) is a recently identified small-molecule HIV-1 attachment inhibitor with good anti-

viral activity and pharmacokinetic properties [32]. BMS-378806 binds directly to gp120 with a stoichiometry of approximately 1:1 and with a binding affinity similar to that of soluble CD4. The potential BMS-378806 target site was localized to a specific region within the CD4 binding pocket of gp120 using HIV-1 gp120 variants carrying either compound-selected resistant substitutions or gp120-CD4 contact site mutations [32]. M426L (C4) and M475I (V5) substitutions located at or near gp120/CD4 contact sites were shown to confer high levels of resistance to the *in vitro* mutated HIV-1 variants, suggesting that the CD4 binding pocket of gp120 was the antiviral target. M434I and other secondary changes (V68A and I595F) also affect the drug susceptibility of recombinant viruses, presumably by influencing the gp120 conformation [33]. BMS-378806 (Figure 2) exhibited decreased, but still significant activity against subtype C viruses, low activity against viruses from subtypes A and D, and poor or no activity against subtypes E, F, G, and Group O viruses [33].

BMS-488043 (Figure 2) is a novel and unique small-molecule that inhibits the attachment of HIV-1 to CD4<sup>+</sup> lymphocytes. BMS-488043 exhibits potent antiviral activity against macrophage-, T-cell-, and dual-tropic HIV-1 laboratory strains (subtype B) and potent antiviral activity against a majority of subtype B and C clinical isolates [34]. Data from a limited number of clinical isolates showed that BMS-488043 exhibited a wide range of activity against the A, D, F, and G subtypes, with no activity observed against three subtype AE isolates [34]. The antiviral activity, pharmacokinetics, viral susceptibility, and safety of BMS-488043 were evaluated in an eight-day monotherapy trial that demonstrated significant reductions in viral load. To examine the effects of BMS-488043 monotherapy on HIV-1 sensitivity, phenotypic sensitivity assessment of baseline and post-dosing (day 8) samples were performed. The analyses revealed that four subjects showed emergent phenotypic resistance. Population sequencing and sequence determination of the cloned envelope genes revealed five gp120 mutations at four loci (V68A, L116I, S375I/N, and M426L) associated with BMS-488043 resistance; the most common (substitution at the 375 locus) located near the CD4 binding pocket [35].

**NBD-556 and NBD-557:** Targeting the functionally important and conserved CD4bs on HIV-1 gp120 represents an attractive potential approach to HIV-1 therapy or prophylaxis. Recently, a new class of small-molecule CD4 mimics was identified [36-38]. These compounds, which include the prototypic compound, NBD-556, and its derivatives, mimic the effects of CD4 by inducing the exposure of the co-receptor-binding site on gp120 [17,39]. NBD-556 and -557 (Figure 2) show potent cell fusion and virus-cell fusion inhibitory activity at low (micromolar) concentrations. A mechanistic study showed that both compounds target viral entry by inhibiting the binding of gp120 to its cellular receptor, CD4. A surface plasmon resonance study showed that these compounds bind to unliganded HIV-1 gp120, but not to CD4 [37]. Another recent study identified NBD-analogs as CD4 mimetics that were used for the prophylaxis and treatment of HIV-1 infection [39]. These compounds inhibited HIV-1 transmission by inhibiting the binding of the natural ligand, CD4, and prematurely triggering the envelope glycoprotein to undergo irreversible conformational changes. NBD-556 binds to the F43 cavity, which is formed by binding of gp120 to the CD4 receptor in a highly conserved manner [17,39].

Recently, our group reported that NBD-556 has potent neutralizing antibody-enhancing activity toward plasma antibodies that cannot access neutralizing epitopes hidden within the trimeric Env, such as gp120-CD4 induced epitope (CD4i) and anti-V3 antibodies [17]. Therefore, to investigate the binding site of NBD-556 on gp120, we in-

duced HIV-1 variants that were resistant to NBD-556 *in vitro*. Two amino acid substitutions (S375N in C3 and A433T in C4) were identified at passage 21 in the presence of 50  $\mu$ M NBD-556. The profiles of the resistance mutations after selection with NBD-556 and sCD4 were very similar with regard to their three-dimensional positions.

Elucidation of the detailed molecular mechanisms governing the interaction between gp120 and NBD compounds will enable the optimization and evaluation of this strategy in more complex biological models of HIV-1 infection. Consequently, we will continue to synthesize NBD analogs and search for drugs with greater potency to change the tertiary structure of the envelope glycoproteins and reduce host cytotoxicity [40,41].

**Palmitic acid** : Previous studies with whole *Sargassum fusiforme* (*S. fusiforme*) extract and with the bioactive SP4-2 fraction demonstrated inhibition of HIV-1 infection in several primary and transformed cell lines [42]. Palmitic acid (PA), which was isolated from the SP4-2 bioactive fraction, specifically block productive X4 and R5-tropic HIV-1 infection [43]. PA occupies a novel hydrophobic cavity on the CD4 receptor that is constrained by amino acids F52-to-L70 [44], which encompass residues that have been previously identified as a region critical for gp120 binding. PA is mainly developed as microbicides [45].

### Resistance to CCR5 antagonists

**CCR5 antagonists**: The binding of HIV-1 to CD4 molecules induces conformational change in gp120, resulting in the recognition of either


CCR5 or CXCR4 as a coreceptor for HIV-1 (Figure 1). It has been shown that CCR5-utilizing HIV-1 (R5 virus) is associated with human-to-human transmission that predominate throughout the infection, while CXCR4-utilizing HIV-1 (X4 virus) emerges during the late stage of infection in approximately half of HIV-1-infected individuals and is associated with disease progression [46]. Most strikingly, it had been shown that homozygous individuals having a 32-bp deletion in the CCR5 coding region (CCR5 $\Delta$ 32) were found to be resistant to R5 HIV-1 and remained apparently healthy [47,48]. These findings suggested that CCR5 would be an attractive therapeutic target for treating HIV-1 infection, although it is a host factor. Several small molecule compounds have been developed and were found to bind CCR5 and inhibit R5 virus replication [49-53]. Molecular studies using CCR5 mutants indicated that these compounds bind to a cavity formed by transmembrane helices of CCR5, and thereby inducing the conformational change in an allosteric manner that is not recognized by gp120 of HIV-1 [54-58]. Among these, TAK-779 (Figure 3) was the first compound developed [49] that could inhibit not only HIV-1 infection, but also binding of RANTES (CCR5 ligand) to CCR5-expressing cells at nanomolar concentrations, but was terminated due to poor oral bioavailability. Maraviroc (MVC, UK427, 857) (Figure 3), however, has been approved and used in the clinic for the treatment of HIV-1 infection [8]. Another promising drug, vicriviroc (VCV, SCH-D, SCH-417690) (Figure 3), recently completed phase III trials but has not yet been approved [53].

**Resistance to CCR5 antagonists**: Although CCR5 antagonists target

### Profile of CCR5 antagonist-resistant mutants

drug	virus used		resistant-related mutations		references
	virus name or <i>in vivo</i>	subtype	V3	Non-V3	
AD101	CC1/85	B	H305R, H308P, A316V, G321E	none	[60, 78]
TAK-779	JR-FL <sub>V331b</sub>	B	I304V, H305N, I306M, F312L, E317D	none	[63]
TAK-652	KK	unknown	ND <sup>a</sup>	ND	[59]
VVC	CC1/85	B	none	G516V, M518V, F519I (gp41)	[69, 84, 85]
VVC	RU570	G	K305R, R315Q, K319T	P437S (C4)	[64, 81]
VVC	S91	D	Q315E, R321G	E328K, G429R (C4)	[65]
VVC	<i>in vivo</i>	C	K305R, T307I, F316I, T318R, G319E	none	[67]
MVC	CC1/85	B	A316T, I323V	ND	[61]
MVC	JR-FL <sub>V331b</sub>	B	I304V, F312W, T314A, E317D, I318V	T199K, T275M (C2)	[62]
MVC	<i>in vivo</i>	B	P/T308H, T320H, I322V	D407G, $\Delta^b$ N386 (V4)	[66]

<sup>a</sup>ND, not determined; <sup>b</sup> $\Delta$ , deletion



**Figure 3:** Profile of CCR5 antagonist-resistant mutants. The CCR5 antagonist-resistant mutants were isolated *in vitro* and *in vivo* across different subtypes of HIV-1. Resistance-related mutations were found in the V3 and non-V3 regions including the C2, V4, C4, and gp41. Chemical structures of representative CCR5 antagonists are shown.

a host cell receptor, the *in vitro* [59-64] and *in vivo* [65-67] emergence of viruses resistant to CCR5 antagonists in different subtypes has been reported, as shown in Figure 3. The most intuitive mechanism of resistance to CCR5 antagonists is likely to be the acquisition of CXCR4 use or selection of minority variants of CXCR4- or dual/mixed-tropic viruses [61,68-70]. Numerous studies showed that coreceptor selectivity of HIV-1 is primarily dependent on the third hypervariable region (V3 loop) of gp120 [71-74]. Furthermore, there is a simple rule to predict HIV-1 coreceptor usage called the 11/25 rule: if either the 11th or 25th amino acid position of V3 is positively charged, the virus will use CXCR4 as the coreceptor, otherwise it will use CCR5 [75]. Thus, a single amino acid substitution in the V3 loop is sufficient to acquire usage of CXCR4. However, these are rare cases when the viruses exclusively use CCR5.

Indeed, escape variants from selective pressure by natural ligand for CCR5, such as MIP-1 $\alpha$  (CCL3) [76], or CCR5 antagonists [60], still use CCR5 and do not involve acquisition of CXCR4 usage. These studies indicate that acquisition of CXCR4 usage conferred by mutations in the V3 loop of gp120 results in the loss of replication fitness, as previously described [77]. However, the escape variants from CCR5 antagonists usually retain CCR5 usage [60,61,69,78], and recognize the antagonist-bound form of CCR5 as well as the free CCR5 form for entry by the accumulation of multiple amino acid mutations, called non-competitive resistance [61,79]. In non-competitive resistance, once saturating concentrations of antagonists were achieved, further inhibition was not observed, resulting in the plateau of inhibition, while competitive resistance can achieve inhibition of viral replication by a sufficient inhibitor concentration, resulting in a shift in the IC<sub>50</sub> value (Figure 4). A principal determinant for the reduced sensitivity to CCR5 antagonists has been shown to be the V3 loop of gp120 although the mutations appear to be isolate-specific and antagonist-dependent [33].


In general, primary R5 viruses or laboratory-adapted R5 infectious clones cultured in stimulated peripheral mononuclear cells (PBMCs) have been used for the selection of CCR5 antagonist-resistant variants. However, the use of PBMCs for virus passage is donor-dependent and labor-intensive. Additionally, the use of a single clone for selection would need long-term passage to induce resistant viruses. To overcome these problems, we constructed R5-tropic infectious clones containing a V3 loop library, HIV-1<sub>V3Lib</sub>. To construct replication competent HIV-1<sub>V3Lib</sub>, we chose 10 amino acid positions in the V3 loop and incorporated random combinations of the amino acid substitutions derived from 31 subtype B R5 viruses into the V3 loop library (Figure 5). This novel

*in vitro* system enabled the selection of escape variants from CCR5 antagonists over a relatively short time period.


In addition to the V3 library, we are currently using PM1/CCR5 cells for virus passages. The PM1/CCR5 cell line was generated by standard retrovirus-mediated transduction of parental PM cell line with the CCR5 gene, as previously described [63,76], and is highly sensitive to the R5 viruses compared to the parental PM1 cell line. Remarkably, the infection of PM1/CCR5 cells with R5 viruses induces prominent cell fusion, which is clear sign of virus proliferation. Thus, the use of PM1/CCR5 cells with the HIV-1<sub>V3Lib</sub> allows us to focus on the contribution of the V3 loop in gp120 in CCR5 antagonist-resistance with a shortened selection period compared to the use of PBMCs with wild-type virus. As expected, we were able to isolate TAK-779- [63] and MVC-resistant [62] variants using replication competent HIV-1<sub>V3Lib</sub>. Indeed, TAK-779- and MVC-resistant variants were determined to contain several amino acid substitutions within the V3 loop sequence. However, MVC-resistant variants also contained several amino acid substitutions in non-V3 regions (T199K and T275M), such as elsewhere in the gp120 to retain infectivity [80,81]. However, these mutations could not confer non-competitive resistance, indicating the importance of the V3 loop for non-competitive resistance.

**Mechanisms of resistance:** It is thought that docking of gp120 to CCR5 without CCR5 antagonists involves interactions of both the V3 tip with the second extracellular loop of CCR5 (ECL2) and the V3 stem-C4 region (bridging sheet) with the CCR5 N-terminus (NT) [82]. Since small molecule inhibitors interact with the pocket formed by transmembrane helices, thereby inducing allosteric conformational change in the ECL2, the wild-type virus can no longer interact with the ECL2. It is assumed that binding of small molecule inhibitors alters orientation between the ECL2 and NT regions, disrupting multi-point binding sites for gp120, thereby impeding gp120-CCR5 interaction [83]. Indeed, studies using CCR5 mutants showed that the escape variants were more dependent on tyrosine-sulfated CCR5 NT than wild-type viruses [65,66,84]. Furthermore, these escape variants were more sensitive to monoclonal antibodies recognizing the NT portion of CCR5 [65]. These studies indicated that the escape variants from CCR5 antagonists showed enhanced interactions with the NT that may be a consequence of a weakened interaction with the ECL2 (Figure 6).


Another genetic pathway is independent of V3 mutations. Vicriviroc-resistant mutants have been developed with multiple amino acid substitutions throughout the gp120 spanning the C2-V5 region without any changes in the V3 loop [69]. Recently, three amino acid changes in the fusion peptide domain of gp41 have been shown to be responsible for resistance although the effect of these mutations was



**Figure 4:** Typical competitive and non-competitive resistance profiles. Competitive resistance can achieve inhibition of viral replication by a sufficient inhibitor concentration, resulting in a shift in the IC<sub>50</sub> value (left panel). In non-competitive inhibition, increasing concentrations of inhibitors have no effect, resulting in no increase in the inhibitory effect (right panel).



**Figure 5:** Schematic structure of HIV-1 V3 loop library showing introduced mutations in V3 for the analysis of escape mutants. Residues in boldface indicate the substitutions that were randomly incorporated in the V3 loop, possible  $>2 \times 10^4$  combinations. The amino acid substitutions were detected in 31 R5 clinical isolates.



**Figure 6:** Resistant HIV-1 viruses can enter host cells in the presence of the CCR5 antagonist. The successful viral fusion requires the interaction of the V3 loop in gp120 with the ECL2 and NT of CCR5. CCR5 antagonists bind to the pocket formed by TM helices and induce allosteric conformational changes in the ECL2, thereby disrupting the interaction of gp120 with CCR5. The CCR5 antagonists-resistant viruses containing multiple amino acid substitutions in the V3 loop can recognize antagonist-bound forms of CCR5 by enhanced interaction with the NT.

context-dependent [84,85]. Thus, the mechanisms by which changes in the fusion peptide alter the gp120-CCR5 interaction still remain to be determined.

As previously mentioned, the patterns of mutations in escape variants against CCR5 antagonists were hypervariable and context-dependent, due in part to extensive sequence heterogeneity of HIV-1 *env*. Resistance to CCR5 antagonists was also found to be dependent upon cellular conditions such as cell tropism and the availability of CCR5. The differential staining of CCR5-expressing cells by various CCR5 monoclonal antibodies suggested that CCR5 exists in heterogeneous forms [86] and compositions of these multiple forms differed in cell type [87]. These findings suggested that different conformations of CCR5 with CCR5 antagonists might induce different substitutions in gp120. Moreover, the development of cross-resistance to other CCR5 antagonists is inconsistent, where some studies suggest that it may occur [69,78,79] and some suggest that it may not occur [61]. Additional data from *in vitro* and *in vivo* studies will be needed to elucidate the meaning of these studies.

### Resistance to CXCR4 antagonists

**CXCR4 as a target:** CXCR4 is a coreceptor that is used for entry by X4-tropic viruses [88]; however, it is not always regarded as a suitable

therapeutic target molecule for HIV-1 infection (Figure 1). R5 and X4 HIV-1 variants are both present in transmissible body fluids; however, R5-tropic HIV-1 transmits infection and dominates the early stages of HIV-1 pathogenesis [89], whereas X4-tropic HIV-1 evolves during the later stages and leads to acceleration of disease progression due to faster decline in CD4<sup>+</sup> T lymphocytes [90,91]. Coreceptor switching from CCR5 to CXCR4 occurs in approximately 40–50% of infected individuals [92]; in addition, the R5 virus is still present as a minor viral population even after emergence of the X4 virus. Furthermore, CXCR4 deletion in mice was shown to induce a variety of severe disorders and resulted in embryonic lethality [93], suggesting that CXCR4-targeting drugs may be less well tolerated than CCR5 inhibitors. These studies indicate that administration of CXCR4 inhibitors is relatively restricted to the later stage of infection after coreceptor switching. Therefore, the development of CXCR4 antagonists has proceeded at a deliberate pace when compared with that of other types of entry inhibitors.

**Escape from CXCR4 antagonists:** Based on the manner of escape of R5-tropic HIV-1 from CCR5 antagonists, four main resistance pathways may be intuitively possible for X4 HIV-1 escape from CXCR4 antagonists: (i) coreceptor switching from CXCR4 to CCR5; (ii) outgrowth of the pre-existing R5 virus; (iii) decrease in CXCR4 susceptibility by mutation(s) in *Env*; and (iv) utilization of the drug-bound



form of CXCR4. The first mechanism comprises a shift in coreceptor usage from CXCR4 to CCR5, which is induced by selective pressure from CXCR4 antagonists. However, this is unlikely to occur frequently because coreceptor switching from CCR5 to CXCR4, and *vice versa*, requires multiple mutations throughout gp160 via transitional intermediates with poor replication fitness [77].

There is an evolutionary gap in viral fitness between viruses using CXCR4 and those using CCR5. However, an R5X4 dual-tropic virus can shift from X4-dominated tropism to R5-dominated tropism [83]. The R5X4 dual-tropic 89.6 mainly uses CXCR4 as a coreceptor, but after selection with the CXCR4 antagonist T140, coreceptor usage shifted from a phenotype that mainly used CXCR4 to one mainly using CCR5 due to a single amino acid substitution (R308S) in the V3 loop *in vitro*. These results indicated that the R5X4 virus could shift its main coreceptor usage due to a low genetic barrier to the development of resistance. In contrast, an outgrowth of the pre-existing minority of the R5 virus caused by CXCR4 antagonists, is expected to lead to virologic failure. AMD3100 is a small molecule compound called a bicyclam that has potent antiviral activity against a variety of X4-tropic strains [94-99]. However, it is not clinically available because of low oral bioavailability [100]. After treatment of clinical isolates *in vitro* with AM3100 for 28 days, the major population of viruses using CXCR4 was promptly replaced by the pre-existing minor population using CCR5 with multiple mutations in the V3 loop *in vitro* [101].

The third possible pathway results from accumulation of mutations in the viral envelope that allow interaction between gp120 and the coreceptor in the presence of the inhibitor. AMD3100-resistant viruses selected *in vitro* from NL4-3 strain still used CXCR4 as a coreceptor and contained several mutations in the V3 loop and showed poor fitness [102]. In contrast, other viruses resistant to POL3026, a specific  $\beta$ -hairpin mimetic CXCR4 antagonist, did not show any fitness cost


and contained four mutations (Q310H, I320T, N325D, and A329T) in the gp120 V3 loop [70]. These four mutations were shared by viral strains resistant to SDF-1 $\alpha$  [103] and T134 [104], indicating that the V3 loop is a crucial region for the acquisition of CXCR4 antagonist resistance.

The fourth possible mechanism involves acquisition of the ability to utilize the inhibitor-bound form as well as the drug-free form of CXCR4 for viral entry. Several clinical isolates demonstrate infection through the AMD3100-bound form of CXCR4, indicating a non-competitive mode of drug resistance [99]. The V1/V2 region of one of the isolates is responsible for this property, suggesting that baseline resistance to this kind of CXCR4 antagonist should be considered while developing CXCR4 antagonists. Recent advances have led to the development of orally-active CXCR4 antagonists, including AMD11070 [105], KRH-3955 [106], and GSK81297 [107]. Therefore, to prevent the possible emergence of pre-existing forms of the CCR5 virus, it is likely that CXCR4 antagonists will be effective only in combination with a CCR5 antagonist or other antiviral drugs.

### Fusion inhibitory peptides and their mechanisms of action

Fusion inhibitors: Enfuvirtide (T-20) was approved by the FDA in 2003 as the first fusion inhibitor that efficiently suppresses the replication of HIV-1 resistant to available classes of anti-HIV-1 drugs (Figure 1), such as reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs). Hence, it has been widely used for treatment of HIV-1 infected patients where treatment with other antiretroviral drugs has failed [108]. T-20 comprises a 36 amino acid peptide derived from the gp41 HIV-1 C-terminal heptad repeat (C-HR), as shown in Figure 7.

During HIV-1 entry, binding of gp120 to CD4 and either CCR5 or CXCR4 initiates penetration of the hydrophobic fusion peptide domain at the N-terminal heptad repeat (N-HR) of gp41 into the target



**Figure 7:** Schematic view of HIV-1 gp41 functional domains and mutation map for T-20. Putative hydrophobic pocket region of the N-HR is shown (green) and may form a leucine-zipper-like domain. In the C-HR, two tryptophan-rich domains (TRD; pink) are located at the N- and C-terminal regions (N-TRD and C-TRD, respectively). The N-TRD binds to the hydrophobic pocket in the N-HR, whereas the C-TRD plays a key role in membrane association. FP; fusion peptide domain, which penetrates into the target cell membrane. TM; transmembrane region. The amino acid sequence of the HXB2 clone is shown as a representative HIV-1 sequence. Only mutations located in the extracellular domain of gp41 are shown. Mutations observed *in vitro* and *in vivo* selections are indicated by an asterisk (\*). I37T was only selected *in vitro*. Primary and secondary mutations were most frequently associated with T-20 resistance (red and blue, respectively). In addition, T25S/A, S35A/T, R46K, L55F, Q56R/K, V72L, A101I/T/V/G, L108Q, N109D, D113G/N, E119Q, L130V, I135L, N140I, and L158W were selected in patients under T-20 containing regimens, but observed in some drug-naïve HIV-1 strains (Los Alamos HIV Sequence Data Bank, <http://www.hiv.lanl.gov/content/index> (natural polymorphisms)). Corresponding regions of T-20, SC34EK, and T2635 are shown. T-20 is comprised of the original sequence but others are extensively modified.

cell membrane [6]. In the gp41 extra-cellular domain, the  $\alpha$ -helical region at the C-HR begins to fold and interact with a trimeric form of the N-HR in an anti-parallel manner. This intramolecular folding forms a stable six-helix bundle and facilitates the fusion of the virus envelope and cellular membranes. During the fusion step of HIV-1 replication, T-20 can interfere with the formation of the six-helix bundle consisting of a trimeric N-HR/C-HR complex.

In the C-HR, two tryptophan-rich domains (TRDs) are located in close proximity to the connection loop (N-TRD) and the membrane-spanning or transmembrane region (C-TRD). Both TRDs resemble a leucine zipper structure and are believed to be important for interactions of the N-HR and the C-HR. T-20 contains the amino acid sequence of the C-TRD, whereas C34-based peptides, such as SC34EK and T2635, contain the N-TRD. T-20 is believed to bind to the N-HR as a decoy and prevents the formation of the six-helix bundle [109], resulting in the inhibition of HIV-1 entry. This mode of action has been well documented with another fusion inhibitory peptide, C34, and remains controversial whether the mechanisms of action of T-20 and C34 are in fact the same.

**Primary and secondary mutations for fusion inhibitors:** Although some fusion peptides, such as N36 [110] and IQN17 [111], are designed using the N-HR sequence, most have been designed using the C-HR sequence. Primary mutations for a representative C-HR derived peptide, T-20, are generally introduced within the N-HR, a putative binding site of T-20 [112,113]. Mutations frequently reported *in vivo* are located at amino acid positions 36–45 of the gp41, including G36D/S/E/V, V38A/M/E, Q40H, N42T, and N43D/K (Figure 7) [114]. Using circular dichroism analysis, others and we clearly demonstrated that these primary mutations reduce the binding affinity of C-peptides with the N-HR [112,115]. This mutation also impairs physiological intra-molecular binding of the C-HR with the N-HR, providing a replication cost [116]. Therefore, HIV-1 develops secondary or compensatory mutations in the C-HR to restore the reduced stabilities of the six-helix bundle by the introduction of primary mutations. N126K, E137K/Q, and S138A [115,117] have been reported *in vivo*, usually in combination with N-HR mutations. Mutations in the C-HR restore the intra-molecular folding/interaction of the C-HR with the N-HR. The enhanced binding affinity by the secondary mutations can be applied to peptide design, such as C34 with N126K and T-20 with S138A, which maintain anti-HIV-1 activity, even to drug-resistant HIV-1 [115].

Secondary mutations of the N-HR are not only non-synonymous, but also synonymous. A part of the RNA coding region for the *env* gene, including gp41, also encodes the Rev-responsible element (RRE), which is an RNA secondary structure important for unspliced RNA export from the nucleus that is required for efficient viral protein synthesis and packaging of genomic RNA [118,119]. Primary mutations at positions 36 and 38 for stem II and at 43 for stem III affect the RRE structure. Synonymous and non-synonymous mutations introduced into the gp41 compensate for RRE structure stability, such as T18A for V38A [120] and A30V for G36D [116], and Q41 (CAG to CAA) and L44 (UUG to CUG) for N43D [121]. This association between the gp41 and RRE results in some genetic restrictions.

**Impact of mutations on clinical potency:** Only one or two amino acid substitutions in gp41 appear to be sufficient for clinical treatment failure, where after the emergence of mutations, viral load gradually increases [122]. For example, G36E, V38A, Q40H, and N43D were shown to confer 39.3-, 16-, 21-, and 18-fold reductions in susceptibility to T-20, respectively [123]. Double or triple substitutions have also been identified in clinical isolates from patients undergoing ther-

apy with T-20. Mutations such as N42T+N43S, V38A+N42D, and Q40H+L45M confer 61-, 140-, and 67-fold reductions in susceptibility to T-20, respectively [123]. Mutations at codons 36 (G36E/D/S) and 38 (V38A/G/M) seem to emerge relatively rapidly *in vivo*, whereas Q40H and N43D emerge more slowly [122]. After prolonged therapy, HIV-1 has been shown to develop secondary mutations and may confer more apparent resistance with improved replication kinetics. Therefore, combination regimens with other inhibitors, such as RTIs and PIs, are indispensable for sufficient positive viral responses.

T-20 appears to inhibit replication of HIV-1 subtype independent-ly [124–126], since T-20 has mainly been used for subtype B HIV-1 infected patients. Based on the mechanism of action of T-20, interference of N- and C-HR interactions may be expected, where amino acid sequences are highly conserved across all subtypes. However, in non-B subtype HIV-1, N42S predominantly emerged as a resistance-related mutation [124,125].

**Resistance to the next generation inhibitors:** Next generation inhibitors have been designed using several strategies, such as the introduction of specific amino acid motifs and secondary mutations into the sequence of the original peptide inhibitors [115] to enhance the stability of the  $\alpha$ -helical structure between inhibitors and fusion domain at the N-HR. In contrast to T-20, primary mutations to third generation inhibitors were not selected *in vitro* [127,128]; therefore, the accumulation of multiple mutations is likely necessary for the development of resistance. In the case of SC34EK, 13 amino acid substitutions (D36G, Q41R, N43K, A96D, N126K, E151K, H132Y, V182I, P203S, L204I, S241F, H258Q, and A312T) were introduced and single amino acid substitutions only conferred weak resistance (<6-fold) [127]. For another peptide, T-2635, 12 amino acids in 10 positions (A6V, L33S, Q66R/L, K77E/N, T94N, N100D, N126K, H132Q, E136G, and E151G) were selected, and single mutations did not confer resistance to T-2635 [128]. Interestingly, some of these mutations were located outside the N-HR and C-HR. Cross-resistance between SC34EK and T-2635 was only examined for the SC34EK-resistant virus and revealed little cross-resistance [127]. Further studies of resistance profiles might be helpful in defining new strategies for the design of fusion inhibitors that can suppress the replication of resistant variants of HIV-1.

## Conclusion

The emergence of viruses resistant to entry inhibitors, as well as other classes of antiviral agents (reverse transcriptase or protease inhibitors), has been reported *in vitro* and *in vivo*. Resistance to entry inhibitors, including attachment inhibitors and coreceptor antagonists, is mainly conferred as a result of missense mutations within the gp120 subunit of the *env* gene, which differ from one inhibitor to another. Alternatively, treatment failure can occur through the expansion of pre-existing CXCR4-using virus for CCR5 antagonists, and vice versa. Agents that target gp41-dependent fusion select for HIV-1 variants with mutations within the gp41 envelope gene. These results indicate the incredible flexibility of the HIV-1 genome to escape from a variety of entry inhibitors. Therefore, the development of novel entry inhibitors for clinical use is needed to limit escape mutants by effective combination therapy.

## References

1. Potter SJ, Chew CB, Steain M, Dwyer DE, Saksena NK (2004) Obstacles to successful antiretroviral treatment of HIV-1 infection: problems & perspectives. *Indian J Med Res* 119: 217-237.

2. Shafer RW, Schapiro JM (2008) HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. *AIDS Rev* 10: 67-84.
3. Gupta RK, Gibb DM, Pillay D (2009) Management of paediatric HIV-1 resistance. *Curr Opin Infect Dis* 22: 256-263.
4. Wild C, Greenwell T, Matthews T (1993) A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. *AIDS Res Hum Retroviruses* 9: 1051-1053.
5. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. *Cell* 89: 263-273.
6. Chan DC, Kim PS (1998) HIV entry and its inhibition. *Cell* 93: 681-684.
7. Westby M, van der Ryst E (2010) CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. *Antivir Chem Chemother* 20: 179-192.
8. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. *Antimicrob Agents Chemother* 49: 4721-4732.
9. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. *Nat Med* 11: 1170-1172.
10. Moore JP, Kuritzkes DR (2009) A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. *Curr Opin HIV AIDS* 4: 118-124.
11. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. *Science* 280: 1884-1888.
12. Sattentau QJ, Moore JP (1993) The role of CD4 in HIV binding and entry. *Philos Trans R Soc Lond B Biol Sci* 342: 59-66.
13. Ugolini S, Mondor I, Sattentau QJ (1999) HIV-1 attachment: another look. *Trends Microbiol* 7: 144-149.
14. ES, Li XL, Moudgil T, Ho DD (1990) High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. *Proc Natl Acad Sci U S A* 87: 6574-6578.
15. Orloff SL, Kennedy MS, Belperron AA, Maddon PJ, McDougal JS (1993) Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. *J Virol* 67: 1461-1471.
16. McKeating J, Balfe P, Clapham P, Weiss RA (1991) Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity. *J Virol* 65: 4777-4785.
17. Yoshimura K, Harada S, Shibata J, Hatada M, Yamada Y, et al. (2010) Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. *J Virol* 84: 7558-7568.
18. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassiliatos LS, et al. (2004) Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. *Antimicrob Agents Chemother* 48: 423-429.
19. Bodart V, Anastassov V, Darkes MC, Idzan SR, Labrecque J, et al. (2009) Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. *Biochem Pharmacol* 78: 993-1000.
20. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, et al. (2004) Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. *J Infect Dis* 189: 286-291.
21. Toma J, Weinheimer SP, Stawiski E, Whitcomb JM, Lewis ST, et al. (2011) Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. *J Virol* 85: 3872-3880.
22. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, et al. (2005) Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. *J Virol* 79: 1252-1261.
23. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, et al. (2005) Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. *Proc Natl Acad Sci U S A* 102: 13372-13377.
24. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. *Science* 326: 285-289.
25. DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. *Science* 266: 1024-1027.
26. T, Xu L, Dey B, Hessel AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. *Nature* 445: 732-737.
27. H, Stamatatos L, Ip JE, Barbas CF, Parren PW, et al. (1997) Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. *J Virol* 71: 6869-6874.
28. Wu X, Zhou T, O'Dell S, Wyatt RT, Kwong PD, et al. (2009) Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. *J Virol* 83: 10892-10907.
29. Wu X, Yang ZY, Li Y, Hoger Corp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. *Science* 329: 856-861.
30. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. *Science* 329: 811-817.
31. Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, et al. (2011) Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. *J Virol* 85: 8954-8967.
32. Guo Q, Ho HT, Dicker I, Fan L, Zhou N, et al. (2003) Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. *J Virol* 77: 10528-10536.
33. Lin PF, Blair W, Wang T, Spicer T, Guo Q, et al. (2003) A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. *Proc Natl Acad Sci U S A* 100: 11013-11018.
34. Fransen S, Bridger G, Whitcomb JM, Toma J, Stawiski E, et al. (2008) Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition. *Antimicrob Agents Chemother* 52: 2608-2615.
35. Zhou N, Nowicka-Sans B, Zhang S, Fan L, Fang J, et al. (2011) *In vivo* patterns of resistance to the HIV attachment inhibitor BMS-488043. *Antimicrob Agents Chemother* 55: 729-737.
36. A, Madani N, Klein JC, Hubicki A, Ng D, et al. (2006) Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. *Biochemistry* 45: 10973-10980.
37. Q, Ma L, Jiang S, Lu H, Liu S, et al. (2005) Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. *Virology* 339: 213-225.
38. Lalonde JM, Elban MA, Courter JR, Sugawara A, Soeta T, et al. (2011) Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. *Bioorg Med Chem* 19: 91-101.
39. Madani N, Schon A, Princiotta AM, Lalonde JM, Courter JR, et al. (2008) Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. *Structure* 16: 1689-1701.
40. Narumi T, Ochiai C, Yoshimura K, Harada S, Tanaka T, et al. (2010) CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. *Bioorg Med Chem Lett* 20: 5853-5858.
41. Yamada Y, Ochiai C, Yoshimura K, Tanaka T, Ohashi N, et al. (2010) CD4 mimics targeting the mechanism of HIV entry. *Bioorg Med Chem Lett* 20: 354-358.
42. EE, Lin X, Li W, Cotter R, Klein MT, et al. (2006) Inhibition of highly productive HIV-1 infection in T cells, primary human macrophages, microglia, and astrocytes by Sargassum fusiforme. *AIDS Res Ther* 3: 15.
43. Lee DY, Lin X, Paskaleva EE, Liu Y, Puttamadappa SS, et al. (2009) Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection. *AIDS Res Hum Retroviruses* 25: 1231-1241.
44. Paskaleva EE, Xue J, Lee DY, Shekhtman A, Canki M (2010) Palmitic acid analogs exhibit nanomolar binding affinity for the HIV-1 CD4 receptor and nanomolar inhibition of gp120-to-CD4 fusion. *PLoS One* 5: e12168.
45. Lin X, Paskaleva EE, Chang W, Shekhtman A, Canki M (2011) Inhibition of HIV-

- 1 infection in ex vivo cervical tissue model of human vagina by palmitic acid; implications for a microbicide development. *PLoS One* 6: e24803.
46. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR (1997) Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. *J Exp Med* 185: 621-628.
47. Liu R, Paxton Wa, Choe S, Ceradini D, Martin SR, et al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. *Cell* 86: 367-377.
48. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, et al. (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. *Nature* 382: 722-725.
49. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, et al. (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. *Proc Natl Acad Sci U S A* 96: 5698-5703.
50. Imamura S, Ichikawa T, Nishikawa Y, Kanzaki N, Takashima K, et al. (2006) Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity. *J Med Chem* 49: 2784-2793.
51. Maeda K, Yoshimura K, Shibayama S, Habashita H, Tada H, et al. (2001) Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. *J Biol Chem* 276: 35194-35200.
52. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, et al. (2001) SCH-C (SCH 351125), an orally bioavailable, smallmolecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection *in vitro* and *in vivo*. *Proc Natl Acad Sci U S A* 98: 1-6.
53. Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, et al. (2004) Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-(2-methoxy-1(R)-4-(trifluoromethyl)phenyl)ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Sele. *J Med Chem* 47: 2405-2408.
54. Dragic T, Trkola a, Thompson Da, Cormier EG, Kajumo Fa, et al. (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. *Proc Natl Acad Sci USA* 97: 5639-5644.
55. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, et al. (2004) Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 *in vitro*. *J Virol* 78: 8654-8662.
56. Imamura S, Nishikawa Y, Ichikawa T, Hattori T, Matsushita Y, et al. (2005) CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives. *Bioorg Med Chem* 13: 397-416.
57. Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, et al. (2006) Interaction of small molecule inhibitors of HIV-1 entry with CCR5. *Virology* 349: 41-54.
58. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, et al. (2003) Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. *J Virol* 77: 5201-5208.
59. Baba M, Miyake H, Wang X, Okamoto M, Takashima K (2007) Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. *Antimicrobial agents and chemotherapy* 51: 707-715.
60. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, et al. (2002) HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. *Proc Natl Acad Sci U S A* 99: 395-400.
61. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, et al. (2007) Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. *J Virol* 81: 2359-2371.
62. Yuan Y, Maeda Y, Terasawa H, Monde K, Harada S, et al. (2011) A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc. *Virology* 413: 293-299.
63. Yusa K, Maeda Y, Fujioka A, Monde K, Harada S (2005) Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. *J Biol Chem* 280: 30083-30090.
64. Ogert RA, Wojcik L, Buontempo C, Ba L, Buontempo P, et al. (2008) Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. *Virology* 373: 387-399.
65. Ogert RA, Hou Y, Ba L, Wojcik L, Qiu P, et al. (2010) Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. *Virology* 400: 145-155.
66. Tilton JC, Wilen CB, Didigu Ca, Sinha R, Harrison JE, et al. (2010) A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. *J Virol* 84: 10863-10876.
67. Tsimbris AMN, Sagar M, Gulick RM, Su Z, Hughes M, et al. (2008) *In vivo* emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. *J Virol* 82: 8210-8214.
68. Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, et al. (2007) Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. *J Infect Dis* 196: 304-312.
69. Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, et al. (2005) Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). *Virology* 338: 182-199.
70. Moncunill G, Armand-Ugón M, Pauls E, Clotet B, Esté Ja (2008) HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants *in vitro*. *Aids* 22: 23-31.
71. Briggs DR, Tuttle DL, Sleasman JW, Goodenow MM (2000) Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). *Aids* 14: 2937-2939.
72. Hu Q, Trent JO, Tomaras GD, Wang Z, Murray JL, et al. (2000) Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. *J Mol Biol* 302: 359-375.
73. N, Haraguchi Y, Takeuchi Y, Soda Y, Kanbe K, et al. (1999) Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. *Virology* 259: 324-333.
74. Verrier F, Borman AM, Brand D, Girard M (1999) Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage. *AIDS Res Hum Retroviruses* 15: 731-743.
75. Resch W, Hoffman N, Swanstrom R (2001) Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. *Virology* 288: 51-62.
76. Maeda Y, Foda M, Matsushita S, Harada S (2000) Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. *J Virol* 74: 1787-1793.
77. Pastore C, Ramos A, Mosier DE (2004) Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. *J Virol* 78: 7565-7574.
78. Kuhmann S, Pugach P, Kunstman K (2004) Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. *J Virol* 78: 2790-2807.
79. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, et al. (2007) HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. *Virology* 361: 212-228.
80. Anastassopoulou CG, Marozsan AJ, Matet A, Snyder AD, Arts EJ, et al. (2007) Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. *PLoS pathogens* 3: e79.
81. Ogert RA, Ba L, Hou Y, Buontempo C, Qiu P, et al. (2009) Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. *J Virol* 83: 12151-12163.
82. Huang C-c, Tang M, Zhang M-Y, Majeed S, Montabana E, et al. (2005) Structure of a V3-Containing HIV-1 gp120 Core. *Science* 310: 1025-1028.
83. Maeda Y, Yusa K, Harada S (2008) Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120. *Antiviral Res* 77: 128-135.
84. Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP (2009) Two HIV-1 variants

- resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. *PLoS pathogens* 5: e1000548.
85. Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP (2009) Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. *Proc Natl Acad Sci USA* 106: 5318-5323.
86. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, et al. (1999) Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. *J Biol Chem* 274: 9617-9626.
87. Berro R, Klasse PJ, Lascano D, Flegler A, Nagashima KA, et al. (2011) Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. *J Virol* 85: 8227-8240.
88. Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science* 272: 872-877.
89. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. *J Exp Med* 206: 1273-1289.
90. Moore JP, Kitchen SG, Pugach P, Zack JA (2004) The CCR5 and CXCR4 coreceptors—central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. *AIDS Res Hum Retroviruses* 20: 111-126.
91. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, et al. (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. *J Virol* 66: 1354-1360.
92. Gorry PR, Sterjovskij J, Churchill M, Witlox K, Gray L, et al. (2004) The role of viral coreceptors and enhanced macrophage tropism in human immunodeficiency virus type 1 disease progression. *Sex Health* 1: 23-34.
93. Lapidot T (2001) Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. *Ann N Y Acad Sci* 938: 83-95.
94. De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, et al. (1994) Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. *Antimicrob Agents Chemother* 38: 668-674.
95. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, et al. (1998) AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. *Nat Med* 4: 72-77.
96. Labrosse B, Labernardiere JL, Dam E, Trouplin V, Skrabal K, et al. (2003) Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. *J Virol* 77: 1610-1613.
97. Schols D, Este JA, Henson G, De Clercq E (1997) Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. *Antiviral Res* 35: 147-156.
98. Schols D, Struyf S, Van Damme J, Este JA, Henson G, et al. (1997) Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. *J Exp Med* 186: 1383-1388.
99. Harrison JE, Lynch JB, Sierra LJ, Blackburn LA, Ray N, et al. (2008) Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100. *J Virol* 82: 11695-11704.
100. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, et al. (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. *J Acquir Immune Defic Syndr* 37: 1253-1262.
101. Este JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, et al. (1999) Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. *J Virol* 73: 5577-5585.
102. Armand-Ugon M, Quinones-Mateu ME, Gutierrez A, Barretina J, Blanco J, et al. (2003) Reduced fitness of HIV-1 resistant to CXCR4 antagonists. *Antivir Ther* 8: 1-8.
103. Schols D, Este JA, Cabrera C, De Clercq E (1998) T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. *J Virol* 72: 4032-4037.
104. Kanbara K, Sato S, Tanuma J, Tamamura H, Gotoh K, et al. (2001) Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. *AIDS Res Hum Retroviruses* 17: 615-622.
105. Moyle G, DeJesus E, Boffito M, Wong RS, Gibney C, et al. (2009) Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. *Clin Infect Dis* 48: 798-805.
106. Murakami T, Kumakura S, Yamazaki T, Tanaka R, Hamatake M, et al. (2009) The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. *Antimicrob Agents Chemother* 53: 2940-2948.
107. Jenkinson S, Thomson M, McCoy D, Edelstein M, Danehower S, et al. (2010) Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist. *Antimicrob Agents Chemother* 54: 817-824.
108. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, et al. (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. *N Engl J Med* 348: 2186-2195.
109. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. *Proc Natl Acad Sci U S A* 89: 10537-10541.
110. Chen CH, Matthews TJ, McDanal CB, Bolognesi DP, Greenberg ML (1995) A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. *J Virol* 69: 3771-3777.
111. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. *Cell* 99: 103-115.
112. Rimsky LT, Shugars DC, Matthews TJ (1998) Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. *J Virol* 72: 986-993.
113. Sista PR, Melby T, Davison D, Jin L, Mosier S, et al. (2004) Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. *AIDS* 18: 1787-1794.
114. Marcial M, Lu J, Deeks SG, Ziermann R, Kuritzkes DR (2006) Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. *J Clin Microbiol* 44: 3384-3387.
115. Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, et al. (2009) Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. *J Biol Chem* 284: 4914-4920.
116. Nameki D, Kodama E, Ikeuchi M, Mabuchi N, Otaka A, et al. (2005) Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. *J Virol* 79: 764-770.
117. Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, et al. (2005) Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. *Antimicrob Agents Chemother* 49: 1113-1119.
118. Fischer U, Meyer S, Teufel M, Heckel C, Luhrmann R, et al. (1994) Evidence that HIV-1 Rev directly promotes the nuclear export of unspliced RNA. *EMBO J* 13: 4105-4112.
119. Daugherty MD, Liu B, Frankel AD (2010) Structural basis for cooperative RNA binding and export complex assembly by HIV Rev. *Nat Struct Mol Biol* 17: 1337-1342.
120. Svicher V, Aquaro S, D'Arrigo R, Artese A, Dimonte S, et al. (2008) Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. *J Infect Dis* 197: 1408-1418.
121. Ueno M, Kodama EN, Shimura K, Sakurai Y, Kajiwara K, et al. (2009) Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide. *Antiviral Res* 82: 67-72.

122. Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, et al. (2006) Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 43: 60-64.
123. Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, et al. (2005) Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 79: 12447-12454.
124. Hanna SL, Yang C, Owen SM, Lal RB (2002) Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide [corrected]. AIDS 16: 1603-1608.
125. Pessoa LS, Valadao AL, Abreu CM, Calazans AR, Martins AN, et al. (2011) Genotypic analysis of the gp41 HR1 region from HIV-1 isolates from enfuvirtide-treated and untreated patients. J Acquir Immune Defic Syndr 57 Suppl 3: S197-201.
126. Roman F, Gonzalez D, Lambert C, Deroo S, Fischer A, et al. (2003) Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 33: 134-139.
127. Shimura K, Nameki D, Kajiwara K, Watanabe K, Sakagami Y, et al. (2010) Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors. J Biol Chem 285: 39471-39480.
128. Eggink D, Bontjer I, Langedijk JP, Berkhout B, Sanders RW (2011) Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function. J Virol 85: 10785-19797.

## Submit your next manuscript and get advantages of OMICS Group submissions

### Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

### Special features:

- 200 Open Access Journals
- 15,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.omicsonline.org/submission>

This article was originally published in a special issue, **Pharmacology of Antiretroviral Agents: HIV** handled by Editor(s). Dr. Di Wu, The Children's Hospital of Philadelphia, USA

